MedTrace Logo

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

NCT05624099 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-10-19

No results posted yet for this study

Summary

This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

Conditions

  • Esophageal Neoplasms
  • Esophageal Diseases
  • Digestive System Neoplasms

Interventions

DRUG

camrelizumab

200mg intravenous drip d1q3w

DRUG

Paclitaxel drugs

150mg/m2 d1 q3w

DRUG

Platinum drug

Cisplatin, carboplatin, nedaplatin and other platinum drugs

RADIATION

Radiation

Dose: 5040cGy/28f

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-12-01
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05624099 on ClinicalTrials.gov